ArticlePLoS neglected tropical diseases2025
Spatiotemporal distribution and control of echinococcosis in Xinjiang, 2005-2023.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epidemiological characteristics of Echinococcus granulosus infection in children from some sites in Xinjiang and its association with platelets.BMC infectious diseases · 2026Article
- Therapeutic effects of IL-33/ST-2 pathway inhibition combined with albendazole on hepatic fibrosis and immune regulation in alveolar echinococcosis: in vivo and in vitro evidence.Parasites & vectors · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study investigated the epidemiological characteristics of echinococcosis in Xinjiang, aiming to provide evidence for evaluating prevention and control progress and guiding future strategies.
methodsReported echinococcosis incidence data from Xinjiang during 2005-2023 were obtained from the China Infectious Disease Surveillance and Reporting System. Temporal trends and spatial distributionwere analyzed using joinpoint regression and spatial autocorrelation methods. Additionally, a linear regression model (LR), spatial autoregressive model (SAR), and spatiotemporal autoregressive model (STAR) were constructed to quantitatively assess the impact of factors such as year, spatial lag, and temporal lag on incidence rates.
resultsThe reported incidence ranged from 1.95 per 100,000 in 2005 to 10.85 per 100,000 in 2017, followed by a gradual decline, though levels in 2023 (8.12 per 100,000) remained higher than those in 2005. Spatially, incidence exhibited significant positive spatial correlation (Moran's I: 0.097 in 2008 to 0.400 in 2010, all P-values < 0.001), with high-incidence counties concentrated in northern and central Xinjiang, while low-incidence counties were mainly located in the south. Northern Xinjiang, particularly areas centered around Tacheng Prefecture, Bortala Prefecture, and Ili Prefecture, was identified as a hotspot, whereas Kashgar and Hotan Prefectures in southern Xinjiang formed cold spots. Model analysis indicated that the STAR model provided the best fit (residuals range: 0.020 [-0.292, 0.317], AIC = 2,549.4), with year, spatial lag (β = 0.323), and temporal lag (β = 0.420) significantly affecting incidence rates (P < 0.05). The findings suggest that echinococcosis incidence in Xinjiang exhibits temporal continuity and spatial spillover effects.
conclusionEchinococcosis in Xinjiang exhibited marked spatiotemporal heterogeneity during 2005-2023. While national and regional prevention programs contributed to reducing incidence after 2017, the burden remains substantial. These findings underscore the need for sustained and regionally coordinated prevention and control strategies to prevent potential resurgence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.